公开(公告)号：US20240350680A1

公开(公告)日：2024-10-24

申请号：US18440783

申请日：2024-02-13

Applicant: NOVARTIS AG

Inventor： Matthias EDER ,  Klaus KOPKA ,  Martin SCHÄFER ,  Ulrike BAUDER-WÜST ,  Michael EISENHUT ,  Walter MIER ,  Martina BENESOVA

IPC: A61K51/04 ,  C07B59/00 ,  C07D257/02 ,  C07D295/145

CPC classification number: A61K51/0482 ,  A61K51/0402 ,  A61K51/0497 ,  C07B59/002 ,  C07D257/02 ,  C07D295/145

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

公开(公告)号：US20240293584A1

公开(公告)日：2024-09-05

申请号：US18585905

申请日：2024-02-23

Applicant: The Johns Hopkins University

Inventor： Xing Yang ,  Sridhar Nimmagadda ,  Steven Rowe ,  Stephanie Slania ,  Martin G. Pomper

IPC: A61K51/04 ,  A61K47/54

CPC classification number: A61K51/0485 ,  A61K47/545 ,  A61K51/0478 ,  A61K51/0482

Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) and their use in imaging and treating FAP-α related diseases and disorders are disclosed.

公开(公告)号：US20240216553A1

公开(公告)日：2024-07-04

申请号：US18400969

申请日：2023-12-29

Applicant: Washington University

Inventor： Yongjian Liu ,  Xiuli Zhang ,  Gyu Seong Heo

IPC: A61K51/08 ,  A61K51/04

CPC classification number: A61K51/088 ,  A61K51/0482 ,  A61K2121/00 ,  A61K2123/00

Abstract: Among the various aspects of the present disclosure is the provision of compositions of CD163 targeting and theranostic agents and methods for use in detecting, monitoring, and evaluating CD163 associated diseases, disorders, and conditions.

公开(公告)号：US20240197927A1

公开(公告)日：2024-06-20

申请号：US18541604

申请日：2023-12-15

Applicant: Fusion Pharmaceuticals Inc.

Inventor： Diane-Charlotte Imbs ,  Elodie Lewkowicz ,  Alexander McEwan ,  Thomas Rohban ,  Sylvie Rolland ,  Daniel Stevens ,  John R. Forbes

IPC: A61K51/04 ,  A61K31/7068 ,  A61K47/64 ,  A61P35/00

CPC classification number: A61K51/0482 ,  A61K31/7068 ,  A61K47/643 ,  A61P35/00

Abstract: The present invention relates to a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.

公开(公告)号：US11952368B2

公开(公告)日：2024-04-09

申请号：US17956727

申请日：2022-09-29

Applicant: XIAMEN UNIVERSITY

Inventor： Haojun Chen ,  Liang Zhao ,  Qin Lin ,  Kaili Fu ,  Yizhen Pang ,  Zhide Guo ,  Jianyang Fang ,  Long Sun ,  Hua Wu

IPC: C07D401/14 ,  A61K51/04

CPC classification number: C07D401/14 ,  A61K51/0482

Abstract: Provided are a fibroblast activation protein inhibitor (FAPI) dimer compound, an FAPI dimer-based positron emission tomography (PET) imaging agent for tumor diagnosis, and a preparation method and use thereof. An amphiphilic polyethylene glycol (PEG) chain and a dimerized structure of FAPI in the FAPI dimer compound with a structure shown in formula I can improve the in vivo kinetic properties of the compound and prolong a residence time of the compound in a tumor, thereby improving the uptake and imaging effects in the tumor. The accurate tumor diagnosis can be achieved by labeling the FAPI dimer compound with a diagnostic nuclide (68Ga), which has promising application prospects in PET imaging for diagnosis and in the preparation of a therapeutic nuclide (such as 177Lu or 90Y)-labeled drug for treating a FAP-α-expressing tumor.

公开(公告)号：US11951188B2

公开(公告)日：2024-04-09

申请号：US16979017

申请日：2019-03-07

Applicant: LUMIPHORE, INC.

Inventor： David Tatum ,  Jide Xu ,  Darren Magda ,  Nathaniel Butlin

IPC: A61K51/04 ,  A61K51/08 ,  C07D471/18 ,  C07D491/22 ,  C07F5/00

CPC classification number: A61K51/0482 ,  A61K51/082 ,  C07D471/18 ,  C07D491/22 ,  C07F5/003

Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.

公开(公告)号：US11938201B2

公开(公告)日：2024-03-26

申请号：US18354282

申请日：2023-07-18

Applicant: The Johns Hopkins University

Inventor： Xing Yang ,  Sridhar Nimmagadda ,  Steven Rowe ,  Stephanie Slania ,  Martin G. Pomper

IPC: A61K51/00 ,  A61K47/54 ,  A61K51/04 ,  A61M36/14

CPC classification number: A61K51/0485 ,  A61K47/545 ,  A61K51/0478 ,  A61K51/0482

Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) and their use in imaging and treating FAP-α related diseases and disorders are disclosed.

公开(公告)号：US20240082435A1

公开(公告)日：2024-03-14

申请号：US18547286

申请日：2022-02-25

Applicant: TELIX INTERNATIONAL (INNOVATIONS) PTY LTD

Inventor： Artur Pinto ,  Alexis Bontemps ,  Lucas Lemaire

IPC: A61K51/04

CPC classification number: A61K51/0482 ,  A61K51/0455 ,  A61K2121/00 ,  A61K2123/00

Abstract: The disclosure provides methods for the solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates. The disclosure also relates to key intermediates of this process and methods for their preparation such as a method of preparing a compound of formula (V). Also disclosed are use of the conjugates as precursors for therapeutic and/or diagnostic agents, including treating and diagnosing prostate cancer.

公开(公告)号：US20240075171A1

公开(公告)日：2024-03-07

申请号：US18494042

申请日：2023-10-25

Applicant: Advanced Accelerator Applications

Inventor： Donato Barbato ,  Clementina Brambati ,  Daniela Chicco ,  Francesco de Palo ,  Lorenza Fugazza ,  Maurizio Mariani ,  Giovanni Tesoriere

IPC: A61K51/04 ,  A61K33/24 ,  C22B59/00

CPC classification number: A61K51/048 ,  A61K33/24 ,  C22B59/00 ,  A61K51/0482

Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

公开(公告)号：US20240067650A1

公开(公告)日：2024-02-29

申请号：US18182147

申请日：2023-03-10

Applicant: LUMIPHORE, INC.

Inventor： David Tatum ,  Jide Xu ,  Darren Magda ,  Nathaniel Butlin

IPC: C07D471/18 ,  C07D491/22 ,  C09K11/06

CPC classification number: C07D471/18 ,  C07D491/22 ,  C09K11/06 ,  A61K51/0482

Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.